Dwight Matthias, MD
Endocrinology, Diabetes & Metabolism · Newport News, VANPI 1609805332
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,613 of the $29,402 with a category attached, or 66.7%. 32 manufacturers reported payments, led by Boehringer Ingelheim at 46.6% of the total. Reporting peaked in 2019 at $17,075 and has fallen 95.9% since, to $702 in 2025. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $164.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$14K
- Lilly USA, LLC$12K
- Medtronic$2K
- Novo Nordisk$451
- Amgen$341
- Radius Health, Inc.$196
- plus $1K from 26 others
What the payments were for
- Consulting fees$2,92510%
- Speaking & faculty fees$19,61367%
- Travel & lodging$3,14211%
- Food & beverage$3,53312%
- Education$1891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 38 | $13,699 |
| Lilly USA, LLC | 34 | $11,799 |
| Medtronic(2 entities) | 3 | $1,789 |
| Novo Nordisk | 16 | $451 |
| Amgen | 9 | $341 |
| Radius Health, Inc. | 12 | $196 |
| Sanofi-aventis U.S. LLC | 6 | $107 |
| Dexcom, Inc. | 8 | $102 |
| Bayer | 5 | $88 |
| Merck | 5 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $72 |
| Insulet Corporation | 5 | $68 |
| Corcept Therapeutics | 3 | $65 |
| Ascendis Pharma Endocrinology Inc | 3 | $53 |
| AbbVie | 3 | $50 |
| Mannkind Corporation | 3 | $49 |
| Recordati_rare_diseases_inc. | 2 | $41 |
| Cequr Corporation | 1 | $37 |
| Kyowa Kirin, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $31 |
| IBSA Pharma Inc. | 2 | $31 |
| AstraZeneca | 2 | $31 |
| Shire North American Group Inc | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| GSK | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Abbott | 1 | $17 |
| Tandem Diabetes Care, Inc. | 1 | $13 |
| Lifescan, Inc. | 1 | $13 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$24,048
- MiniMed Quick-set$130
- Repatha$121
- EVENITY$119
- Ozempic$112
- MINIMED 780G$109
How this compares
$29,402 in reported general payments places this provider in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 259 | $455,360 |
| JardianceEmpagliflozin | 178 | $245,594 |
| TrulicityDulaglutide | 113 | $172,756 |
| SynjardyEmpagliflozin/Metformin Hcl | 72 | $93,089 |
| FarxigaDapagliflozin Propanediol | 59 | $81,547 |
| MounjaroTirzepatide | 31 | $69,139 |
| Tresiba Flextouch U-100Insulin Degludec | 73 | $58,001 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 20 | $41,747 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $36,778 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 43 | $30,268 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $29,013 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $24,589 |
| Humalog Kwikpen U-100Insulin Lispro | 108 | $24,388 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $20,060 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 169 | $19,405 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $451 | $462,490291 claims |
| Boehringer IngelheimJardiance, Synjardy | $13,699 | $338,683250 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30, Insulin Lispro | $11,799 | $261,850235 claims |
| AstraZenecaFarxiga | $31 | $81,54759 claims |
| MerckJanumet | $78 | $29,01321 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $107 | $19,81766 claims |
| BayerKerendia | $88 | $15,50824 claims |
| AbbVieSynthroid | $50 | $9,330118 claims |
| IBSA Pharma Inc.Tirosint | $31 | $3,21413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Newport News
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- Domenica RubinoArlington$608K
- Samamtha HudsonMidlothian$372K
- Elias SirajNorfolk$316K
- Allen BurrisPowhatan$261K
- Samim EnayatFairfax$217K
- Denise ArmelliniFairfax$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.